Patent Number: 7,955,602

Title: Annexin proteins and autoantibodies as serum markers for cancer

Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.

Inventors: Hanash; Samir M. (Ann Arbor, MI), Misek; David (Ann Arbor, MI), Hinderer; Robert (Flint, MI), Beer; David (Chelsea, MI), Brichory; Frank (Ann Arbor, MI)

Assignee: Regents of the University of Michigan

International Classification: A61K 49/00 (20060101); G01N 33/574 (20060101); G01N 33/48 (20060101); C12Q 1/66 (20060101)

Expiration Date: 2019-06-07 0:00:00